517 related articles for article (PubMed ID: 9465685)
41. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?
McGillicuddy JW; Weimert NA; Taber DJ; Turner A; Mitchell LA; Wray DW; Egidi MF; Kuppachi S; Hughes MG; Baliga PK; Chavin KD
Transplantation; 2010 May; 89(10):1218-23. PubMed ID: 20410854
[TBL] [Abstract][Full Text] [Related]
42. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Singh N
Rev Med Virol; 2006; 16(5):281-7. PubMed ID: 16878336
[TBL] [Abstract][Full Text] [Related]
43. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
44. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
45. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
46. [Efficacy preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients].
López-Medrano F; Lumbreras C; Otero JR; González-Alegre MT; San Juan R; Folgueira D; Lizasoaín M; Loinaz C; Moreno E; Aguado JM
Med Clin (Barc); 2004 Jan; 122(2):41-5. PubMed ID: 14733853
[TBL] [Abstract][Full Text] [Related]
47. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
Tzakis AG
Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
[TBL] [Abstract][Full Text] [Related]
48. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis.
Boivin G; Erice A; Crane DD; Dunn DL; Balfour HH
J Infect Dis; 1993 Aug; 168(2):332-5. PubMed ID: 8393055
[TBL] [Abstract][Full Text] [Related]
49. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients.
Zaia JA
Clin Infect Dis; 1993 Nov; 17 Suppl 2():S392-9. PubMed ID: 8274605
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).
Uslu A; Ari A; Simsek C; Olgut AI; Karatas M; Aykas A; Tercan IC; Tatar E
Transplant Proc; 2019 Sep; 51(7):2350-2354. PubMed ID: 31358453
[TBL] [Abstract][Full Text] [Related]
51. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
[TBL] [Abstract][Full Text] [Related]
52. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
Conti DJ; Freed BM; Singh TP; Gallichio M; Gruber SA; Lempert N
Arch Surg; 1995 Nov; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
[TBL] [Abstract][Full Text] [Related]
53. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
54. [The prevention of cytomegalovirus infection and disease by administration of biological products].
Ihara T
Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680
[TBL] [Abstract][Full Text] [Related]
55. Prevention of cytomegalovirus disease in transplant recipients.
Winston DJ
Lancet; 1995 Nov; 346(8987):1380-1. PubMed ID: 7475816
[No Abstract] [Full Text] [Related]
56. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones CJ; Craig JC
Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
[TBL] [Abstract][Full Text] [Related]
57. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
[TBL] [Abstract][Full Text] [Related]
58. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.
Boeckh M
Transpl Infect Dis; 1999 Sep; 1(3):165-78. PubMed ID: 11428987
[TBL] [Abstract][Full Text] [Related]
59. Cytomegalovirus infection after renal transplantation: selective prophylaxis and treatment.
Pascual J; Alarcón MC; Marcén R; Burgos FJ; Tato A; Tenorio MT; Liaño F; Ortuño J
Transplant Proc; 2003 Aug; 35(5):1756-7. PubMed ID: 12962783
[TBL] [Abstract][Full Text] [Related]
60. Ganciclovir prophylaxis after lung and heart-lung transplantation.
Halme M; Lautenschlager I; Halme L; Tukiainen P; Mattila S
Transpl Int; 1998; 11 Suppl 1():S499-501. PubMed ID: 9665045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
